Gesynta Pharma AB
Overview
Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients.
Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy.
The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023.
Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.
Contact Details
info@gesynta.se
Stockholm, Sweden
Founded
2017
Employees
10-20
Categories
Keywords
You're invisible in searches for:
Add keywords that describe your company, services, or market to improve your visibility in search results.
Companies teams usually look at after Gesynta Pharma AB
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.